Back to results
US 9,006,184 B2Granted
Cancer vaccine composition
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo Sugiyama
Life of this patent
Estimating the term…
Abstract
A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
Claims5
A method of cancer treatment, comprising administering to an HLA-A*0201-positive person a composition comprising the following peptide:
- a modified peptide of the WT1187 peptide:
- Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO:
- 2) or the WT1126 peptide:
- Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO:
- 3), wherein the modified peptide is a peptide comprising the amino acid residues at position 4 to 8 from the N terminus of the WT1187 or WT1126 peptide and is immunogenic in HLA-A*0201-positive persons.
2 more elements
A method of cancer treatment, comprising administering an HLA-A*0201-positive person a composition comprising:
- a modified peptide of the WT1187 peptide:
- Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO:
- 2) or the WT1126 peptide:
- Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO:
- 3), either of which is a partial peptide of a protein which is a gene product of the tumor suppressor gene WT1, the modified peptide being immunogenic in HLA-A*0201-positive persons.
2 more elements
Dependencies are inferred from the claim text.